key: cord-0681934-sayq8enb
authors: Etyang, A.; Adetifa, I.; Omore, R.; Misore, T.; Ziraba, A. K.; Ng'oda, M.; Gitau, E.; Gitonga, J.; Mugo, D.; Kutima, B.; Karanja, H.; Toroitich, M.; Nyagwange, J.; Tuju, J.; Wanjiku, P.; Aman, R.; Amoth, P.; Mwangangi, M.; Kasera, K.; Ng'ang'a, W.; Akech, D.; Sigilai, A.; Karia, B.; Karani, A.; Voller, S.; Agoti, C. N.; Ochola-Oyier, L. I.; Otiende, M.; Bottomley, C.; Nyaguara, A.; Uyoga, S.; Gallagher, K.; Kagucia, E. W.; Onyango, D.; Tsofa, B.; Mwangangi, J.; Maitha, E.; Barasa, E.; Bejon, P.; Warimwe, G. M.; Scott, J. A. G.; Agweyu, A.
title: SARS-CoV-2 Seroprevalence in three Kenyan Health and Demographic Surveillance Sites, December 2020-May 2021
date: 2022-02-09
journal: nan
DOI: 10.1101/2022.02.07.22270012
sha: fffacb29c594a89c2e2db9a844a496c540ad913c
doc_id: 681934
cord_uid: sayq8enb

Importance Most of the studies that have informed the public health response to the COVID-19 pandemic in Kenya have relied on samples that are not representative of the general population. Objective To determine the cumulative incidence of infection with SARS-CoV-2, from a randomly selected sample of individuals normally resident at three Health and Demographic Surveillance Systems (HDSSs) in Kenya. Design This was a cross-sectional population-based serosurvey conducted at Kilifi HDSS, Nairobi Urban HDSS, and Manyatta HDSS in Kenya. We selected age-stratified samples at HDSSs in Kilifi, Kisumu and Nairobi, in Kenya. Blood samples were collected from participants between 01 Dec 2020 and 27 May 2021. Setting Kilifi HDSS comprises a predominantly rural population, Manyatta HDSS comprises a predominantly semi-urban population, while Nairobi Urban HDSS comprises an urban population. The total population under regular surveillance at the three sites is ~470,000. Exposure We tested for IgG antibodies to SARS-CoV-2 spike protein using ELISA. Locally validated assay sensitivity and specificity were 93% (95% CI 88-96%) and 99% (95% CI 98-99.5%), respectively. Main Outcome and Measures The primary outcome measure was cumulative incidence of infection with SARS-COV-2 virus as evidenced by seropositivity to SARS-CoV-2 whole spike protein. We adjusted our estimates using classical methods and Bayesian modelling to account for assay performance. We performed multivariable logistic regression to test associations between seropositivity and age category, time period and sex. Results We recruited 2,559 individuals from the three HDSS sites, median age (IQR) 27years (10-78) and 52% were female. Seroprevalence at all three sites rose steadily during the study period. In Kilifi, Kisumu and Nairobi, seroprevalences at the beginning of the study were 14.5 % (9.1-21), 36.0 (28.2-44.4) and 32.4 % (23.1-42.4) respectively; at the end they were 27.6 % (21.4-33.9), 42.0 % (34.7-50.0) and 50.2 % (39.7-61.1), respectively. In multivariable logistic regression models that adjusted for sex and period of sample collections, age category was strongly associated with seroprevalence (p<0.001), with the highest seroprevalences being observed in the 35-44 and [≥]65 year age categories. Conclusion There has been substantial unobserved transmission of SARS-CoV-2 in the general population in Kenya. There is wide variation in cumulative incidence by location and age category.

Most of the studies that have informed the public health response to the COVID-19 pandemic in Kenya have relied on samples that are not representative of the general population. We conducted population-based serosurveys at three Health and Demographic Surveillance Systems (HDSSs) to determine the cumulative incidence of infection with SARS-CoV-2.

We selected random age-stratified population-based samples at HDSSs in Kisumu, Nairobi and Kilifi, in Kenya. Blood samples were collected from participants between 01 Dec 2020 and 27 May 2021. No participant had received a COVID-19 vaccine.

We tested for IgG antibodies to SARS-CoV-2 spike protein using ELISA. Locallyvalidated assay sensitivity and specificity were 93% (95% CI 88-96%) and 99% (95% CI 98-99.5%), respectively. We adjusted prevalence estimates using classical methods and Bayesian modelling to account for the sampling scheme and assay performance.

We recruited 2,559 individuals from the three HDSS sites, median age (IQR) 27 (10-78) years and 52% were female. Seroprevalence at all three sites rose steadily during the study period. In Kisumu, Nairobi and Kilifi, seroprevalences (95% CI) at the beginning of the study were 36.0% (28.2-44.4%), 32.4% (23.1-42.4%), and 14.5% (9.1-21%), and respectively; at the end they were 42.0% (34.7-50.0%), 50.2% (39.7-61.1%), and 24.7% (17.5-32 .6%), respectively. Seroprevalence was substantially lower among children (<16 years) than among adults at all three sites (p≤0.001).

. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 9, 2022. ; https://doi.org/10.1101/2022.02.07.22270012 doi: medRxiv preprint

By May 2021 in three broadly representative populations of unvaccinated individuals in Kenya, seroprevalence of anti-SARS-CoV-2 IgG was 25-50%. There was wide variation in cumulative incidence by location and age.

. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 9, 2022. ; https://doi.org/10.1101/2022.02.07.22270012 doi: medRxiv preprint

Kenya has had five waves of SARS-CoV-2 infection as of January 2022. As of 31

December 2021 the official number of reported cases and deaths was 295,028 and 5,378 respectively. 1 The official number of reported cases is widely acknowledged to be an underestimate of the true number of infections. Accurate estimates of the proportion of the population previously infected with SARS-CoV-2 are important to understand the epidemiology of the infection and inform control strategies such as vaccination and non-pharmaceutical interventions. Previous studies have shown significant temporal and spatial heterogeneity in the pattern of infections in Kenya, [2] [3] [4] [5] [6] but these studies had the limitation of not being population-based, instead relying on convenience samples of special population groups such as blood donors, 2, 6 antenatal clinic (ANC) attendees, 5 truck drivers 4 and health care workers (HCW). 3 A similar situation obtains in many low and middle income countries (LMICs), with only a handful of published population based studies having been conducted in Africa, [7] [8] [9] [10] [11] which is home to over one billion people.

Sub-Saharan Africa appears to have had lower mortality from SARS-CoV-2 infections than other parts of the world. One reason that has been proposed for this is that the African population is generally younger. 12 To test this hypothesis, accurate age specific estimates of cumulative incidence of infection are required from population-based studies. These estimates can then be used to determine agespecific infection fatality rates. However, previous studies have been susceptible to several biases, including the absence of children in studies of blood donors, the restriction of ANC studies to females, and potentially higher exposure to SARS-CoV-2 among HCWs and truck drivers. In addition, many of these studies have over-. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) 6 sampled urban residents, yet majority of the people in sub-Saharan Africa live in rural areas.

We report results from the first round of a population-based survey for presence of SARS-CoV-2 antibodies at three [13] [14] [15] health and demographic surveillance sites broadly representative of the population of Kenya.

Following consultations with the Ministry of Health, three representative health and demographic surveillance systems (HDSS's) spread across Kenya were chosen as sites for the serosurveillance study. The sites were as follows: Manyatta HDSS in Kisumu (Western Kenya), 13 Nairobi urban HDSS (Central Kenya), 14 and Kilifi HDSS, 15 (South East Kenya) (Supplementary Figure 1) . The total population under regular surveillance at the three sites is ~470,000. [13] [14] [15] The Kisumu HDSS comprises a semi-urban population. 13 At the median date of sample collection in Kisumu (31 March 2021), the official number of reported cases of SARS-CoV-2 infection in the county was 2,670, and the official number of reported COVID-19 deaths was 24.

The Nairobi HDSS comprises an urban population. 14 At the median date of sample collection in Nairobi (28 March 2021), the official number of reported cases of SARS-CoV-2 infection in the county was 60,836, and the official number of reported COVID-19 deaths was 984.

. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted February 9, 2022. ; https://doi.org/10.1101/2022.02.07.22270012 doi: medRxiv preprint

The Kilifi HDSS comprises a predominantly rural population. 15 At the median date of sample collection in Kilifi (17 Feb 2021) , the official number of reported cases of SARS-CoV-2 infection in the county was 2,613, and the official number of reported COVID-19 deaths was 21.

At each of the three sites, we randomly selected an age-stratified sample of 50 individuals in each 5-year age band from 15-65+ years and above, and 100 in each 5-year age band from 0-14 years. A sample of 300 participants <15 years old would suffice to estimate seroprevalence of 1% with a 2% margin of error, and a sample of 550 participants aged ≥ 15 years would suffice to estimate seroprevalence of 3-5% with a <5% error margin.

Participants were selected from population lists of residents at the HDSS sites, which in the pre-pandemic period were updated at least twice a year. Surveillance activities at all sites were temporarily halted from March to September 2020 because of the disruption caused by the pandemic. Following approval from regulatory authorities and the Ministry of Health fieldwork activities resumed prior to the serosurvey, as this was deemed an essential public health activity.

Inclusion criteria for the study were that the individual should be a resident of the HDSS and provide consent. Potential participants were excluded if they had a bleeding disorder or other medical contraindication for venipuncture.

December 2020 and 27 May 2021. Potential participants that could not be found after three attempts were replaced by randomly selected individuals meeting the same age and sex category as the originally selected individual.

. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted February 9, 2022. ; https://doi.org/10.1101/2022.02.07.22270012 doi: medRxiv preprint

Ethical approval for conducting the study and publication of these data was obtained from the Kenya Medical Research Institute Scientific and Ethics Review Unit (KEMRI/SERU/CGMR-C/203/4085). Written informed consent (and assent where applicable) was obtained from all participants, or their guardians before their participation in the study.

Study staff administered a questionnaire to the participants either electronically or on paper, to collect data on demographic and clinical characteristics, including whether the individual had experienced symptoms compatible with COVID-19 in the preceding six months. None of the study participants had received any dose of a COVID-19 vaccine at the time of sample collection.

They then collected 5ml (2ml in children under 5 years) of venous blood from each participant. Serum was obtained by centrifuging the samples at 450 x g for 5 minutes. Serum samples were then stored in -80ºC freezers at the study sites before being transported in dry ice to the KEMRI-Wellcome Trust research laboratories in Kilifi for assays.

All samples were tested at the KEMRI-Wellcome Trust Research Programme laboratories in Kilifi for IgG to SARS-CoV-2 whole spike protein using an adaptation of the Krammer Enzyme Linked Immunosorbent Assay (ELISA). 16 Validation of the assay was described previously. 6 Briefly, sensitivity, estimated in 174 SARS-CoV-2 PCR positive Kenyan adults in Nairobi and a panel of sera from the UK National . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 9, 2022. pre-pandemic period), was 99.0% (95% CI 98.1-99.5). Results were expressed as the ratio of test OD to the OD of the plate negative control; samples with OD ratios greater than two were considered positive for SARS-CoV-2 IgG.

In the primary analysis, we estimated seroprevalence at each site based on the weighted proportion of samples with an OD ratio >2. The study period was divided into six 30-day periods and separate seroprevalence estimates were computed for each period. For site specific age-stratified analyses, we used three time periods of 60 days each. We adjusted the seroprevalence estimates for assay sensitivity and specificity using both classical 17 and Bayesian modelling 18 . Summary estimates for each site were weighted to account for underlying population, age, and sex structure at the study sites. In the Bayesian modelling, non-informative priors were used for all parameters, and the models were fitted using the Rstan software package 19 , as with previous studies. 3, 6 We tested whether seropositivity was associated with sex, age, or period of sample collection using multivariable logistic regression.

All analyses were conducted using Stata™ Version 15 software (College Station, Texas, USA) and R version 3.6.1 (Vienna, Austria).

. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 9, 2022. ;

We recruited 2,559 individuals from the three health and demographic surveillance sites (Figure 1) Overall, seroprevalence in males (32.7%, 95% CI 29.6-36%) did not differ significantly from seroprevalence in females (33.8%, 95% CI 30.8-37.2%). Significant sex differences were not apparent in site specific analyses (Supplementary Table   S1 ). Table 2 displays Bayesian adjusted age specific seroprevalence at each of the three sites over three 60-day intervals. Variation in seroprevalence with age was significant at each of the three sites (P=0.002 in Kisumu and P<0.001 Nairobi and . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 9, 2022.

Kilifi) and the pattern of variation was similar at each site. Across the whole study period seroprevalence was substantially lower among children aged <16 years than among older individuals at each site. In Kisumu seroprevalence in individuals aged <16 years and ≥ 16 years was 29.1% (95% CI 23.7-35%) and 43.8% (95% CI 39.1-49%), respectively; in Nairobi, it was 29.1% (95% CI 23.7-35%) and 47.6% (95% CI 42.6-52.8%), respectively; in Kilifi it was 14.5% (95% CI 10.4-19.2%) and 25.1% (95% CI 21.1-29.3%), respectively.

Results of analyses where we used classical methods to adjust for assay sensitivity and specificity were essentially similar to the Bayesian adjusted estimates (Tables S1 and S2).

. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 9, 2022. ;

In this population-based serosurveillance study using a locally-validated assay at three sites broadly representative of Kenya, we found that 25-50% of the resident populations had SARS-CoV-2 antibodies by the end of our study in May 2021. As none of the study participants had received a COVID-19 vaccine the presence of anti-spike antibodies indicates previous infection. There were large temporal, agerelated and geographical differences in seroprevalence; in particular, older individuals and those in the urban areas of Kisumu and Nairobi had higher seroprevalence.

Our results are generally consistent with other community surveys conducted in Kenya at a roughly similar time point during the pandemic. In two household surveys conducted in Nairobi in November-December 2020, overall seroprevalence was 34.7% and 43.3%, 10,20 where we found a seroprevalence of 32.4% in Nairobi in January 2021; we observed similar age related seroprevalence patterns compared to the previous surveys.

Our results from this population-based survey were also generally consistent with those obtained from special population groups in Kenya. This provides assurance that previous studies among other populations in Kenya have been broadly representative of seroprevalence trends. For example, seroprevalence among health care workers in Nairobi from July to December 2020 was 44%, 3 compared to 32% in the general population of the Nairobi HDSS in January 2021. Seroprevalence among blood donors in the counties in which Kisumu, Nairobi, and Kilifi are located were 38%, 62% and 43% respectively in January to March 2021 21 , compared to 40%, 47% and 25% during March 2021 in the present study (Table 1) . Of note studies of . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 9, 2022. ;  blood transfusion donors are restricted to individuals aged 16-65 years who have substantially higher seroprevalence than children or older adults in our study.

Seroprevalence estimates from other population samples showed geographical variations of similar magnitude to those observed in the present study. Comparisons between different sampling methods are highly susceptible to confounding as illustrated above.

A significant strength of this study is the random sampling of a defined population.

The results are therefore more generalizable to the Kenyan population than previous studies that involved special populations. [2] [3] [4] [5] [6] Although there had been two other population-based studies 10,20 conducted earlier, both were limited to Nairobi, the capital city of Kenya. Our inclusion of other sites in this study, far removed from Nairobi, helps to provide broader insights into the extent of the SARS-CoV-2 pandemic in Kenya. Another strength is that we used an assay that had been rigorously validated using samples from the local population and reference panels from the National Institute for Biological Standards and Control (NIBSC) in the UK, as well as the WHO. 22, 23 A key limitation of the study is that we were unable to fully account for waning of antibodies, which could have led to an underestimation of seroprevalence. In a previous study, we undertook mixture modelling, 24 which does not rely on thresholds, but instead assumes that the population sampled consists of two groups with different distributions of antibody levels; this suggested that the threshold-based method was significantly underestimating the true seroprevalence. We were however unable to conduct similar analysis for this dataset, as the mixture modelling requires control data from the respective sites which we did not have.

. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 9, 2022. ;

An additional limitation was the fact that nearly half of those who were targeted through the random sampling were not present at home. These were in most cases individuals who had gone to their workplaces. Given that these individuals would have had more interactions with others both at the workplace and during commuting, it is likely that the seroprevalence figures presented here are an underestimate of the true value.

In conclusion, in this population-based study at three health and demographic surveillance sites, broadly representative of the population in Kenya, we found that between a quarter and a half of the population had evidence of previous infection by May 2021, though with marked variation in infection risk by age and geographical region.

. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 9, 2022. ; is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 9, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 9, 2022. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 9, 2022. ; SARS-CoV-2 Seroprevalence in three Kenyan Health and Demographic Surveillance Sites, December 2020-May 2021 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted February 9, 2022. ; . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted February 9, 2022. ; Figure S1 : Location of study sites within Kenya . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted February 9, 2022. ;

Temporal trends of SARS-CoV-2 seroprevalence during the first wave of the COVID-19 epidemic in Kenya

Seroprevalence of Antibodies to Severe Acute Respiratory Syndrome Coronavirus 2 Among Healthcare Workers in Kenya

Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Immunoglobulin G Antibody Seroprevalence among Truck Drivers and Assistants in Kenya

Sero-surveillance for IgG to SARS-CoV-2 at antenatal care clinics in two Kenyan referral hospitals

Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Kenyan blood donors

Seroprevalence of severe acute respiratory syndrome coronavirus 2 IgG in Juba

Community SARS-CoV-2 seroprevalence before and after the second wave of SARS-CoV-2 infection in Harare

Seroprevalence of SARS-CoV-2 after the Second Wave in South Africa in HIV-Infected and Uninfected Persons: A Cross-Sectional Household Survey

Seroprevalence and risk factors of SARS-CoV-2 infection in an urban informal settlement in

Seroepidemiology and model-based prediction of SARS-CoV-2 in Ethiopia: longitudinal cohort study among front-line hospital workers and communities

The puzzle of the COVID-19 pandemic in Africa

Health and Demographic Surveillance Systems within the Child Health and Mortality Prevention Surveillance Network

Health & Demographic Surveillance System Profile: The Nairobi Urban Health and Demographic Surveillance System (NUHDSS)

Profile: The Kilifi Health and Demographic Surveillance System (KHDSS)

A serological assay to detect SARS-CoV-2 seroconversion in humans

Estimating prevalence from the results of a screening test

Bayesian analysis of tests with unknown specificity and sensitivity

High seroprevalence of SARS-CoV-2 but low infection fatality ratio eight months after introduction in

Prevalence of SARS-CoV-2 Antibodies From a National Serosurveillance of Kenyan Blood Donors

Baillie on behalf of the ISARICC Investigators

We thank Nelson Mbaya, Salma Musa, Boniface Ingumba Butichi and Nicholas Kiprono Mutai for their roles in data, laboratory and field work management in Nairobi. We thank Victor Akelo, Beth A. Tippet Barr, Dickson Gethi, Kephas Otieno and Frederick Oluoch for their technical support before and during implementation of

Supplementary Appendix